These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22972762)

  • 1. A critical evaluation of the tumor-targeting properties of bispecific antibodies based on quantitative biodistribution data.
    Hemmerle T; Wulhfard S; Neri D
    Protein Eng Des Sel; 2012 Dec; 25(12):851-4. PubMed ID: 22972762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-targeting antibody-anticalin fusion proteins for in vivo pretargeting applications.
    Steiner M; Gutbrodt K; Krall N; Neri D
    Bioconjug Chem; 2013 Feb; 24(2):234-41. PubMed ID: 23350721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.
    Pasche N; Wulhfard S; Pretto F; Carugati E; Neri D
    Clin Cancer Res; 2012 Aug; 18(15):4092-103. PubMed ID: 22693354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.
    Frey K; Zivanovic A; Schwager K; Neri D
    Integr Biol (Camb); 2011 Apr; 3(4):468-78. PubMed ID: 21225052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
    Hess C; Neri D
    Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses.
    Stamova S; Feldmann A; Cartellieri M; Arndt C; Koristka S; Apel F; Wehner R; Schmitz M; Bornhäuser M; von Bonin M; Ehninger G; Bartsch H; Bachmann M
    Anal Biochem; 2012 Apr; 423(2):261-8. PubMed ID: 22274538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted delivery of calreticulin to ED-A fibronectin leads to tumor-growth retardation.
    Ziffels B; Grötsch A; Al-Bayati L; Neri D
    J Biotechnol; 2019 Jan; 290():53-58. PubMed ID: 30579890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.
    Villa A; Trachsel E; Kaspar M; Schliemann C; Sommavilla R; Rybak JN; Rösli C; Borsi L; Neri D
    Int J Cancer; 2008 Jun; 122(11):2405-13. PubMed ID: 18271006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
    Biburger M; Weth R; Wels WS
    J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel synthetic naïve human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin.
    Villa A; Lovato V; Bujak E; Wulhfard S; Pasche N; Neri D
    MAbs; 2011; 3(3):264-72. PubMed ID: 21487243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
    Cardillo TM; Karacay H; Goldenberg DM; Yeldell D; Chang CH; Modrak DE; Sharkey RM; Gold DV
    Clin Cancer Res; 2004 May; 10(10):3552-61. PubMed ID: 15161715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor targeting properties of antibody fusion proteins based on different members of the murine tumor necrosis superfamily.
    Hemmerle T; Hess C; Venetz D; Neri D
    J Biotechnol; 2014 Feb; 172():73-6. PubMed ID: 24384233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
    van Schaijk FG; Broekema M; Oosterwijk E; van Eerd JE; McBride BJ; Goldenberg DM; Corstens FH; Boerman OC
    J Nucl Med; 2005 Jun; 46(6):1016-22. PubMed ID: 15937314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and characterization of bispecific costimulatory molecules containing a minimized CD86 (B7-2) domain and single-chain antibody fragments for tumor targeting.
    Rohrbach F; Gerstmayer B; Biburger M; Wels W
    Clin Cancer Res; 2000 Nov; 6(11):4314-22. PubMed ID: 11106249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion.
    Johnson S; Burke S; Huang L; Gorlatov S; Li H; Wang W; Zhang W; Tuaillon N; Rainey J; Barat B; Yang Y; Jin L; Ciccarone V; Moore PA; Koenig S; Bonvini E
    J Mol Biol; 2010 Jun; 399(3):436-49. PubMed ID: 20382161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
    Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
    Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and characterization of anti-renal cell carcinoma x antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma.
    Kranenborg MH; Boerman OC; Oosterwijk-Wakka JC; de Weijert MC; Corstens FH; Oosterwijk E
    Cancer Res; 1995 Dec; 55(23 Suppl):5864s-5867s. PubMed ID: 7493361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy with bispecific antibodies.
    Thielemans KM
    Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.